Abe O, Nomura Y, Izuo M, Tominaga T, Koyama H, Tashiro H
Dept. of Surgery, ST. Luke's International Hospital.
Gan To Kagaku Ryoho. 1991 Jul;18(8):1333-6.
Tamoxifen (TAM), an antiestrogen was administered 20 mg b.i.d. to 20 patients with recurrent breast cancer at the time of first relapse who had been treated with the adjuvant therapy including TAM 10 mg b.i.d.. Patients who had been treated with TAM at least 1 year and in which the relapse had occurred after 3 months or more after the cessation of adjuvant treatment were enrolled in the study. Sixteen patients were evaluated, and a complete response was observed in 3 (19%), partial response in 1 (6%), no change in 5 (31%), and progressive disease in 7 (44%). The response rate was shown to be 25% with 95% confidence interval: 3.8-46.2%. The duration of response ranged from 23+ to 32 weeks. Patients who have received postoperative adjuvant therapy including TAM and have relapsed after the cessation of therapy may retain hormone dependency in responding to a further TAM treatment at the time of relapse of malignancy.
他莫昔芬（TAM），一种抗雌激素药物，对20例首次复发时接受过包括每日两次10毫克TAM辅助治疗的复发性乳腺癌患者，给予每日两次20毫克的剂量。曾接受TAM治疗至少1年且在辅助治疗停止3个月或更长时间后出现复发的患者被纳入该研究。对16例患者进行了评估，观察到3例（19%）完全缓解，1例（6%）部分缓解，5例（31%）病情无变化，7例（44%）疾病进展。显示缓解率为25%，95%置信区间为：3.8 - 46.2%。缓解持续时间为23 +至32周。接受过包括TAM的术后辅助治疗且在治疗停止后复发的患者，在恶性肿瘤复发时对进一步的TAM治疗可能仍保持激素依赖性。
